Ophthal

Your Article Summary

See Latest Articles

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials
Annals of Rheumatic Diseases, 06/09/09

Sieper J et al. – Study demonstrates that in ankylosing spondylitis (AS) patients, rates of uveitis events with etanercept were lower than with placebo in placebo-controlled trials and similar to sulfasalazine in an active-comparator trial.

• Aim was to assess uveitis (including iritis and iridocyclitis) incidence from clinical trials of etanercept in AS pts
• 4 placebo-controlled; 1 active-controlled; and 3 open-label trials were examined for reports of uveitis
• Between-group differences in the uveitis rates were calculated for the double-blind, active-controlled, and long-term studies

• In placebo-controlled trials, the uveitis rate per 100 subject yrs for etanercept was lower vs placebo
• In the active comparator trial, rates for etanercept and sulphasalazine were similar
• Long-term rate for etanercept, estimated from both placebo-controlled and open-label extension studies was 12.0

Today in Uveitis...keeping you current

Receive free subspecialty "5-minute updates" via email

Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09

Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis
Rheumatology International, 11/02/09

Behcet disease: treatment of vascular involvement in children
European Journal of Pediatrics, 10/12/09

See All of Uveitis